Medtronic Is Testing the 200-Day Average and I Am Not Too Optimistic

Prices are testing the October and November lows and also testing the rising 200-day moving average line.

I See No Technical Reason to Approach Teva Pharmaceuticals From the Long Side

Jim Cramer was bearish on TEVA.

Eli Lilly's Technical Setup Looks So-So, So Be Ready to Take Action

A close below $105 for the drugmaker's shares would be bearish based on its charts.

Teladoc Needs to Tell a Technical Analyst the Trend Is Lower

Teladoc is not showing enough positive technical clues to warrant purchase.

Let's Get Real About Johnson & Johnson's Selloff and How to Play the Stock

I find a lot of Reuters' claims hard to believe. Even more difficult to believe is the selloff.

Sagging Centene Appears Vulnerable to Further Declines

Shares of the healthcare company are showing unhealthy tendencies right now after a federal judge rules Obamacare unconstitutional.

Here's a Handful of Small Biotechs Where Insiders Are Buying

Quotient Limited, Iovance Biotherapeutics and AVEO Pharmaceuticals are among the names seeing insider purchases.

Jim Cramer: What to Buy in This Treacherous Market

Look for the big-cap stocks that only come in on tough days -- and take advantage of their weakness at the open.

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Once the safest stocks in the book, the big-cap drug companies are now toxic.

Curaleaf Stock Stumbles as Multi-State Landscape Gets Crowded

The stock closed down on its first day of trading on the CSX. Here is a breakdown of the current landscape and some up-and-comers to keep an eye on.